An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

PF-03814735 is a novel, reversible inhibitor of Aurora kinases A and B that finished a phase I clinical trial for the treatment of advanced solid tumors. To find predictive biomarkers of drug sensitivity, we screened a diverse panel of 87 cancer cell lines for growth inhibition upon PF-03814735 treatment. Small cell lung cancer (SCLC) and, to a lesser extent, colon cancer lines were very sensitive to PF-03814735. The status of the Myc gene family and retinoblastoma pathway members significantly correlated with the efficacy of PF-03814735. Whereas RB1 inactivation, intact CDKN2A/p16, and normal CCND1/Cyclin D1 status are hallmarks of SCLC, activation or amplification of any of the three Myc genes (MYC, MYCL1, and MYCN) clearly differentiated cell line sensitivity within the SCLC panel. By contrast, we found that expression of Aurora A and B were weak predictors of response. We observed a decrease in histone H3 phosphorylation and polyploidization of sensitive lines, consistent with the phenotype of Aurora B inhibition. In vivo experiments with two SCLC xenograft models confirmed the sensitivity of Myc gene-driven models to PF-03814735 and a possible schedule dependence of MYC/c-Myc–driven tumors. Altogether our results suggest that SCLC and other malignancies driven by the Myc family genes may be suitable indications for treatment by Aurora B kinase inhibitors. Mol Cancer Ther; 11(3); 710–9. ©2012 AACR.

[1]  M. Loda,et al.  The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. , 2006, Cancer research.

[2]  S. Warner,et al.  Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer , 2008, Current oncology reports.

[3]  F. Kaye,et al.  Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. , 1994, Oncogene.

[4]  R. Beijersbergen,et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.

[5]  Yingdong Zhao,et al.  Analysis of Gene Expression Data Using BRB-Array Tools , 2007, Cancer informatics.

[6]  S. Robinson,et al.  The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo , 2011, Molecular Cancer Therapeutics.

[7]  L. Pustilnik,et al.  PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy , 2010, Molecular Cancer Therapeutics.

[8]  J. Battey,et al.  L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer , 1985, Nature.

[9]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[10]  P. Kaestner,et al.  Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells , 2009, Molecular Cancer Therapeutics.

[11]  Oliver Gautschi,et al.  Aurora Kinases as Anticancer Drug Targets , 2008, Clinical Cancer Research.

[12]  N. Ahmad,et al.  Regulation of mitosis via mitotic kinases: new opportunities for cancer management. , 2008, Molecular cancer therapeutics.

[13]  C. Cole,et al.  COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .

[14]  Mark A. Hall,et al.  Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. , 2010, Blood.

[15]  J. Battey,et al.  Human small-cell lung cancers show amplification and expression of the N-myc gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Schwartz,et al.  Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. , 2009, Molecular biology of the cell.

[17]  R. Vibhakar,et al.  Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines , 2010, Pediatric blood & cancer.

[18]  Jens C. Streibig,et al.  Bioassay analysis using R , 2005 .

[19]  F. Schabel,et al.  Quantitative evaluation of anticancer agent activity in experimental animals , 1977 .

[20]  C. Dang,et al.  c-Myc Overexpression Uncouples DNA Replication from Mitosis , 1999, Molecular and Cellular Biology.

[21]  R Tibshirani,et al.  Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification , 2006, Oncogene.

[22]  Terence P. Speed,et al.  Estimation and assessment of raw copy numbers at the single locus level , 2008, Bioinform..

[23]  Jianhua Yang,et al.  Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma , 2009, Molecular Cancer Therapeutics.

[24]  Stephen S. Taylor,et al.  Validating Aurora B as an anti-cancer drug target , 2006, Journal of Cell Science.

[25]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[26]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[27]  W. Vainchenker,et al.  Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. , 2010, Blood.

[28]  S. Emanuel,et al.  The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. , 2005, Cancer research.

[29]  Mathias Schmidt,et al.  Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[30]  J. Minna,et al.  Amplification and expression of the c-myc oncogene in human lung cancer cell lines , 1983, Nature.